Medtech industry urges US FDA to relax deadlines for responding to post-market surveillance study orders
This article was originally published in Clinica
Executive Summary
US medtech industry association AdvaMed has asked the to address the "extremely aggressive" statutory deadline for companies to respond to device post-market surveillance studies ordered under Section 522 of the Federal Food, Drug and Cosmetic Act.